Skip to main content
OncoPrescribe
  • HOME
  • WHY US
  • ABOUT
  • SIGN IN
  • SIGN UP

Top Ad

oncoprescribe-top

Advertisement

PORTRAZZA® (Necitumumab)

June 4, 2016April 5, 2020 RR FDA Approvals
Lung Cancer: Non-Small Cell

The FDA on November 24, 2015 granted approval to PORTRAZZA® in combination with Gemcitabine and Cisplatin for first-line treatment of patients with metastatic squamous Non-Small Cell Lung Cancer (NSCLC). PORTRAZZA® is not indicated for treatment of non-squamous NSCLC and is a product of Eli Lilly and Company.

Related Posts:

  • FDA Approves PORTRAZZA® for Metastatic Squamous…

Post navigation

OPDIVO® (Nivolumab)
Daily Aspirin May Improve Survival after Diagnosis of Colorectal Cancer

Bottom Ad

hem-onc-updates

Advertisement

Subscribe

Subscribe

Ad 1

oncoprescribe-ad

Advertisement

Ad 2

OncoPrescribe

Advertisement

Ad 3

OncoPrescribe.com-Ad

Advertisement

Ad 4

Immunization Schedule

Advertisement

  • HELP
  • PRIVACY
  • TERMS
  • DISCLAIMER
  • CONTACT
OncoPrescribe, LLC. All Rights Reserved